Free Trial
LON:DNL

Diurnal Group (DNL) Share Price, News & Analysis

Diurnal Group logo

About Diurnal Group Stock (LON:DNL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
27.30
27.30
52-Week Range
N/A
Volume
145,283 shs
Average Volume
483,617 shs
Market Capitalization
£46.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

Receive DNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter.

DNL Stock News Headlines

Trump’s Strange “Midnight Tweet” Could Trigger Massive Gains
President Trump sends out explosive tweets at all hours of the day... And the market reacts violently. According to one Wall Street legend, Americans can target as much as 627% within HOURS. You have to see how to target these massive profits (from Trump’s latest tweets) for yourself....
Da Nang Port Logistics JSC DNL
D&L Industries Inc
D&L Industries Inc (DNL)
D&L Industries Inc.
See More Headlines

DNL Stock Analysis - Frequently Asked Questions

Diurnal Group plc (LON:DNL) posted its earnings results on Tuesday, September, 15th. The company reported ($4.30) EPS for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40.

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Active Energy Group (AEG), C3.ai (AI), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), B&M European Value Retail (BME) and Cerecor (CERC).

Company Calendar

Last Earnings
9/15/2020
Today
6/05/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
LON:DNL
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.68 million
Price / Cash Flow
2.81
Book Value
GBX 12.70 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£46.33 million
Optionable
Not Optionable
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (LON:DNL) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners